Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cyclacel Pharmaceuticals ( (CYCC) ) has shared an update.
On February 26, 2025, Cyclacel Pharmaceuticals announced a significant change in control and leadership following the completion of a Securities Purchase Agreement. Datuk Dr. Doris Wong Sing Ee acquired a controlling interest in Cyclacel, becoming the new CEO and Executive Director, while Kiu Cu Seng was appointed as the Chief Financial Officer. This transition marks a strategic shift for Cyclacel, potentially impacting its operations and market positioning. The company also experienced several board resignations and new appointments, indicating a broader restructuring effort.
More about Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines. The company specializes in cell cycle, transcriptional regulation, and mitosis biology, with key programs evaluating fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor, for treating patients with solid tumors and hematological malignancies.
YTD Price Performance: -13.24%
Average Trading Volume: 2,442,543
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.61M
Find detailed analytics on CYCC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue